G42
G42, the leading UAE-based AI and cloud computing company and global nonprofit ocean exploration organization OceanX, along with G-Tech Digital Asia (G-Tech), and the Government of the Republic of Indonesia via its Coordinating Ministry for Maritime Affairs and Investment (CMMAI) have announced the signing of a Letter of Intent to establish a collaboration to develop ocean research to help protect the marine environment.
In furtherance of this proposed collaboration, G42 intends to deploy G42 Cloud’s large-scale cloud infrastructure and services, remote sensing drone systems by Bayanat, a public listed company at ADX in which G42 owns a majority stake, and cutting-edge marine genomics applications by G42 Healthcare in the support of OceanX’s social welfare mission and its world-class marine research and media vessel the R/V OceanXplorer, to conduct advanced, in-depth analysis of the coastal and oceanic environments.
The Letter of Intent was signed by Mohammad Firman Hidayat, Acting Deputy Coordinating Minister for Maritime Resources, Peng Xiao, Group CEO of G42, Vincent Pieribone, Vice Chairman of OceanX and Michel Hamilton, CEO of G-Tech.
The collaboration will support the aims of the Indonesian government, led by CMMAI, to improve management of marine resources including biodiversity and conservation of ecosystems, through the use of new technology and methodologies and OceanX’s broader mission to explore the ocean and bring it back to the world through educational media.
The project recognizes the importance of detailed mapping of marine resources through advanced technologies in order to protect and preserve the ocean environment and the livelihoods of the communities that are reliant on it. G42 will support OceanX and CMMAI research with a focus on mapping fisheries and marine resources through data-driven e-DNA, socio-economic, and ecological characters in coastal-marine ecosystems. The proposed collaboration also includes training and knowledge transfer to build human capacity and supporting infrastructure for CMMAI.
In line with the UAE’s mandate to explore and leverage advanced technologies to spearhead the efforts towards environmental preservation, G42 is deploying its extensive portfolio of companies to develop new and better ways in which both public and private organizations can address some of the most pressing climate and environmental challenges.
Peng Xiao, Group CEO of G42 commented: “We are proud to be collaborating with CMMAI and OceanX on this project to develop a greater understanding of Indonesia’s marine environment. Better data is vital to developing a more holistic view of our oceans’ condition, and through our work with OceanX, we are looking to support the development of new, tailored solutions and technologies that will help local authorities to protect the marine environment, for the benefit of present and future generations.”
Dr. Prashanth Marpu, Director of Geospatial Centre Of Excellence and Climate Action Program at Bayanat said: “Oceans are highly complex environments, and monitoring and research can present many challenges to researchers and scientists working in this field. Bayanat is applying its expertise in real-time geospatial services and solutions and handling large-scale data to develop the tools that will allow the research community to leverage big data analysis of the maritime environment.”
About G42
G42 is a global leader in creating visionary artificial intelligence for a better tomorrow. Born in Abu Dhabi and operating across the world, G42 champions AI as a powerful force for good. Its people are constantly reimagining what technology can do, applying advanced thinking and innovation to accelerate progress and tackle society’s most pressing problems.
G42 is driving change in the region and beyond, joining forces with nations, corporations and individuals to create the infrastructure for tomorrow’s world. From molecular medicine to space travel and everything in between, G42 realizes exponential possibilities, today.
For further information visit www.g42.ai.
About OceanX
Oceanographic Research & Exploration Foundation (OceanX) is a mission to support scientists to explore the ocean and to bring it back to the world through captivating media. Uniting leading media, science, and philanthropy partners, OceanX utilizes next-gen technology, fearless science, compelling storytelling, and immersive experiences to educate, inspire, and connect the world with the ocean and build a global community deeply engaged with understanding, enjoying, and protecting our oceans. OceanX is an initiative of Dalio Philanthropies, which furthers the diverse philanthropic interests of Dalio family members.
For more information visit www.oceanx.org and follow OceanX on Facebook, Instagram, Twitter, TikTok and LinkedIn.
About Bayanat
Bayanat, an ADX listed public company with majority shareholding by G42, provides comprehensive world-class AI-powered geospatial solutions to a growing number of sectors such as Defense, Environment, Energy & Resources, Smart Cities and Transportation. It’s offering includes topographic, hydrographic and aeronautical products and charts, as well as spatial data surveying, analysis, management, modelling, visualization and cartography services. Bayanat’s solutions harness vast amounts of premium and unique data from a range of sources including Satellites, High Altitude Pseudo Satellites (HAPS) and Earth Observation powered by AI to drive geospatial intelligence (gIQ).
For more information, please visit: www.bayanat.ai
Twitter:
https://twitter.com/bayanat_ai
LinkedIn:
https://www.linkedin.com/company/bayanatg42/
Instagram:
https://www.instagram.com/bayanat.g42/
Facebook:
https://www.facebook.com/bayanat.g42
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005443/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom